Nitisinona Dipharma (Nitisinone)

Nitisinone, the active ingredient in Nitisinona Dipharma, is a p‑Hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor presented as an oral tablet for oral use. It blocks the formation of toxic metabolites in the tyrosine degradation pathway and is indicated for hereditary tyrosinemia type I, with off‑label use for alkaptonuria.

GNH USA supplies Nitisinona Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for rare‑disease therapies across EU and global markets, and ensuring compliance with local regulatory requirements.

Nitisinona Dipharma (nitisinone) targets disorders of tyrosine metabolism, providing disease‑modifying therapy.

- Hereditary tyrosinemia type I: reduces accumulation of toxic metabolites, improving liver function and survival. - Alkaptonuria (off‑label): lowers homogentisic acid production, potentially slowing ochronotic pigment deposition.

Nitisinona Dipharma may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Fatigue - Skin rash

Serious or Rare Side Effects: - Hepatic dysfunction - Severe allergic reaction - Neutropenia

When prescribing Nitisinona Dipharma, clinicians should observe the following precautions to ensure patient safety.

- Liver function monitoring: assess hepatic enzymes regularly during therapy. - Hematologic monitoring: perform complete blood counts to detect neutropenia. - Renal function assessment: evaluate kidney parameters before and during treatment. - Hypersensitivity risk: discontinue if signs of severe allergic reaction appear. - Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Nitisinona Dipharma can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Warfarin: may potentiate anticoagulant effect and increase INR. - Strong CYP2C9 inhibitors (e.g., fluconazole): can raise nitisinone plasma concentrations.

Moderate Interactions (Monitor Closely): - Antacids: may reduce oral absorption of nitisinone. - Vitamin K supplements: could counteract potential coagulopathy. - High‑protein diet: may influence tyrosine metabolism and drug efficacy.